Advertisement
MARIETTA, Ga., Jan. 23, 2020 /PRNewswire-PRWeb/ -- FiteBacŪ Cavity Cleanser can not only remove debris in carious lesion preparations but can penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface.
Largent Health, LLC announced today receipt of FDA clearance to market FiteBacŪ Cavity Cleanser with 2% K21. Cavity cleansers are intended for cleansing and moistening/re-wetting of prepared dental surfaces prior to completing a restoration.
Largent Health is a company dedicated to bringing innovative antimicrobial technology to healthcare products. "The clearance of Largent Health's FiteBacŪ Cavity Cleanser represents the second FDA regulatory clearance of our FiteBacŪ technology and the first for our K21 molecule" said Kirk Kimmerling, DDS, Founder and CEO of Kimmerling Holdings Group.
FiteBacŪ Cavity Cleanser, with 2% K21, is intended to become part of the restoration/dentin interface by copolymerizing with the dental adhesive. Research shows FiteBacŪ Cavity Cleanser can not only remove debris in carious lesion preparations but also penetrates exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface. Published research supports that a 2% K21 solution is significantly less cytotoxic on human dentin pulp cells than 2% chlorhexidine gluconate, a common component in other cavity cleanser and dental preparations.
"Receipt of our first medical device clearance from FDA represents a significant step forward for all of us at Largent Health and would not have been possible without the efforts of our collaborators and partners, both here in the U.S. as well as overseas.," commented John W. Sharkey, Ph.D., CEO of Largent Health LLC. "With the potential for low cytotoxicity and the ability to promote strong binding of adhesives systems to dentin , we believe FiteBacŪ Cavity Cleanser will become the preferred cavity cleanser for the dental professional."
To learn more about how FiteBacŪ technology is being developed for dental applications please visit http://www.FiteBacDental.com.
SOURCE Largent Health LLC
Advertisement
Largent Health, LLC announced today receipt of FDA clearance to market FiteBacŪ Cavity Cleanser with 2% K21. Cavity cleansers are intended for cleansing and moistening/re-wetting of prepared dental surfaces prior to completing a restoration.
Largent Health is a company dedicated to bringing innovative antimicrobial technology to healthcare products. "The clearance of Largent Health's FiteBacŪ Cavity Cleanser represents the second FDA regulatory clearance of our FiteBacŪ technology and the first for our K21 molecule" said Kirk Kimmerling, DDS, Founder and CEO of Kimmerling Holdings Group.
FiteBacŪ Cavity Cleanser, with 2% K21, is intended to become part of the restoration/dentin interface by copolymerizing with the dental adhesive. Research shows FiteBacŪ Cavity Cleanser can not only remove debris in carious lesion preparations but also penetrates exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface. Published research supports that a 2% K21 solution is significantly less cytotoxic on human dentin pulp cells than 2% chlorhexidine gluconate, a common component in other cavity cleanser and dental preparations.
"Receipt of our first medical device clearance from FDA represents a significant step forward for all of us at Largent Health and would not have been possible without the efforts of our collaborators and partners, both here in the U.S. as well as overseas.," commented John W. Sharkey, Ph.D., CEO of Largent Health LLC. "With the potential for low cytotoxicity and the ability to promote strong binding of adhesives systems to dentin , we believe FiteBacŪ Cavity Cleanser will become the preferred cavity cleanser for the dental professional."
To learn more about how FiteBacŪ technology is being developed for dental applications please visit http://www.FiteBacDental.com.
SOURCE Largent Health LLC
